Skip to main content
Home
About
Field Trip Health
Field Trip Discovery
Field Trip Digital
News
Press Releases
Events and Presentations
In the Media
Stock Information
TSX
NASDAQ
Financials
Quarterly Results
SEDAR Filings
Governance
Board & Advisors
Management Team
Governance Documents
Whistleblower Portal
Contact Us
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Site Search
toggle main menu
News
Home
About
Field Trip Health
Field Trip Discovery
Field Trip Digital
News
Press Releases
Events and Presentations
In the Media
Stock Information
TSX
NASDAQ
Financials
Quarterly Results
SEDAR Filings
Governance
Board & Advisors
Management Team
Governance Documents
Whistleblower Portal
Contact Us
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Normal
Press release year list
2022
2021
2020
2019
01/18/2022
Field Trip Health Ltd. to Participate in Citi’s Psychedelic Drug Video Call Series
01/11/2022
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
01/06/2022
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies
01/05/2022
Field Trip Health Ltd. to Participate in H.C. Wainwright Bioconnect Virtual Conference in January 2022